GLP-1 & Incretin Science

GLP-1 Drugs Beyond Weight Loss

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Incretin agonists have moved well beyond weight and glucose. SELECT demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in 17,604 participants. Further indications including heart failure with preserved ejection fraction, chronic kidney disease and peripheral artery disease have followed or are under regulatory review.

Key facts

SELECT
17,604 participants, 20% MACE reduction
SELECT population
BMI ≥27, established CVD, no diabetes
HFpEF
Under FDA review for semaglutide
HFpEF signal
NYHA class improvement 32.6% vs 21.5%
Kidney disease
FLOW trial: renal events and mortality
Peripheral artery disease
Under review; walking distance endpoint
Retatrutide
CVD and kidney trials within TRIUMPH

Why cardiovascular outcomes changed the category

Weight reduction is a surrogate endpoint. It is assumed to predict benefit, but assumption is not demonstration, and obesity medicines have a long history of failing on hard outcomes. SELECT tested the real question directly in 17,604 people aged 45 or over with a BMI of 27 or above and established cardiovascular disease but no diabetes, across 41 countries, and found a 20% reduction in major adverse cardiovascular events. That converted the class from plausible to demonstrated.

The finding that complicated the story

Post-hoc analysis of SELECT suggested the cardiovascular benefit was not fully explained by the amount of weight lost. If correct, incretin agonism is doing something to cardiovascular risk beyond making people smaller. That would be a different claim about the mechanism, and one that remains under investigation rather than settled.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Heart failure with preserved ejection fraction

HFpEF has been an unusually difficult indication with few effective options. Semaglutide has been under FDA review for HFpEF with obesity, with a prespecified analysis reporting that 32.6% of treated participants improved by at least one NYHA functional class against 21.5% on placebo. Functional class is a patient-relevant measure rather than a laboratory surrogate, which is part of why it drew attention.

Kidney outcomes

The FLOW trial reported reductions in renal events, major adverse cardiovascular events and mortality in people with chronic kidney disease and type 2 diabetes. Kidney and cardiovascular risk are tightly linked, and a compound acting on both is more valuable than one acting on either alone. Retatrutide's programme includes both a cardiovascular outcomes study and a dedicated renal-function trial.

Peripheral artery disease

Semaglutide has been submitted for peripheral artery disease in type 2 diabetes, on trial data reporting improved walking distance and quality of life. Walking distance is a direct functional measure, and PAD is a condition where symptomatic improvement is what patients actually notice.

How to read this expansion sceptically

Each indication rests on its own trial and its own endpoints, and none transfers automatically to another compound in the class. Tirzepatide produces greater weight reduction than semaglutide but does not inherit SELECT's cardiovascular result; that evidence belongs to the molecule that was tested. Outcome data takes years and large populations to generate, which is why the newest and most effective compounds have the least of it.

Frequently asked questions

Does tirzepatide have the same cardiovascular evidence as semaglutide?

No. SELECT tested semaglutide. Outcome evidence belongs to the compound tested and does not transfer across a drug class.

Is the cardiovascular benefit just from weight loss?

Post-hoc analysis of SELECT suggested it was not fully explained by weight reduction, but that remains under investigation rather than established.

Are these indications approved in the UK?

Approvals differ by regulator, indication and product. Several submissions described here have been under review rather than authorised.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.